Celltrion Applies for European Marketing Authorization of 'CT-P16', a Biosimilar of the Anticancer Drug Avastin
[Asia Economy Reporter Minwoo Lee] Celltrion announced on the 12th that it submitted a marketing authorization application for the biosimilar of the anticancer drug Avastin to the European Medicines Agency (EMA) on the 8th. Celltrion stated, "Based on the secured clinical data, we plan to apply for approval in each country through continuous discussions with regulatory authorities."
Hot Picks Today
If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- New Zealand to Cut 8,700 Civil Servants...14% Reduction Deemed 'Unsustainable and Unviable'
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing 90 Degrees These Days Actually Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
